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Abstract We performed reconstitution analyses of functional
interaction between phospholipase A2 (PLA2) and phospholipase
D (PLD) enzymes. Cotransfection of HEK293 cells with
cytosolic (cPLA2) or type IIA secretory (sPLA2-IIA) PLA2
and PLD2, but not PLD1, led to marked augmentation of
stimulus-induced arachidonate release. Interleukin-1-stimulated
arachidonate release was accompanied by prostaglandin E2
production via cyclooxygenase-2, the expression of which was
augmented by PLD2. Conversely, activation of PLD2, not
PLD1, was facilitated by cPLA2 or sPLA2-IIA. Thus, our results
revealed functional crosstalk between signaling PLA2s and
PLD2 in the regulation of various cellular responses in which
these enzymes have been implicated. ß 2000 Federation of
European Biochemical Societies. Published by Elsevier Science
B.V. All rights reserved.
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1. Introduction
Phospholipase A2 (PLA2) catalyzes the hydrolysis of mem-
brane phospholipids, liberating free arachidonic acid (AA)
and lysophospholipids, which are precursors for bioactive lip-
id mediators. Of a number of PLA2 enzymes identi¢ed to
date, cytosolic PLA2K (cPLA2) and several secretory PLA2
(sPLA2) enzymes have been implicated in stimulus-induced
AA release, which is coupled with cyclooxygenase (COX)-cat-
alyzed prostaglandin (PG) formation [1^6]. Activation of
cPLA2 is tightly regulated by post-receptor signal transduc-
tion events, including Ca2 signaling promoted by phospho-
inositide-speci¢c phospholipase C (PLC) enzymes and phos-
phorylation directed by the mitogen-activated protein kinase
(MAPK) members [1,2]. In response to elevated cytoplasmic
Ca2 levels, cPLA2 translocates from the cytosol to the peri-
nuclear membrane [7]. Type IIA sPLA2 (sPLA2-IIA), a signal-
ing sPLA2, accumulates in caveolae signalsomes through
binding to glycosylphosphatidylinositol-anchored heparan sul-
fate proteoglycan glypican [8] and plays an augmentative role
in PG biosynthesis in autocrine, paracrine and juxtacrine fash-
ions [3^5,8,9]. The AA-releasing function and expression of
sPLA2-IIA and its relative sPLA2-V depend on prior activa-
tion of cPLA2 [3,6,10,11].
Phospholipase D (PLD) catalyzes the hydrolysis of phos-
phatidylcholine to produce phosphatidic acid (PA), which by
itself acts as a second messenger or is metabolized to other
signaling molecules, such as lysophosphatidic acid and diac-
ylglycerol (DAG). PLD activation has been implicated in a
wide range of cellular responses, including vesicular transport,
mitogenesis and respiratory burst (reviewed in [12]). There are
at least two PLD isoforms, PLD1 and PLD2, in mammals
[13^17]. PLD1, which exists as two splicing variants (PLD1a
and PLD1b), has low basal activity and is activated by small G
proteins (ARF, Rho and Ral), phosphatidylinositol 4,5-bis-
phosphate (PIP2), and protein kinase CK in vitro [13^16].
PLD1 is distributed primarily on intracellular membranes,
where it may regulate the formation of transport intermedi-
ates [17]. PLD2 is constitutively active and is further stimu-
lated by PIP2 in vitro [18,19], and is localized in caveolae [20].
Each enzyme undergoes unique posttranslational modi¢ca-
tions, including fatty acylation [21] and tyrosine phosphory-
lation [22,23]. However, segregated roles of the two PLD iso-
forms in cellular responses are still poorly understood.
Several lines of evidence have suggested a functional corre-
lation between PLA2 and PLD enzymes during cell activation
[24^30]. We [24] and others [25^27] have reported that stim-
ulus-induced AA release, which appears to be mediated by
cPLA2, is suppressed by pharmacological inhibition of PLD.
Moreover, PLD2, not PLD1, activity has been reported to be
modulated by cPLA2 or its reaction products [28^30]. Anti-
sense suppression of cPLA2 expression leads to a concomitant
reduction of PLD activity in several cell lines predominantly
expressing PLD2 [30]. Since PLA2 and PLD are often simul-
taneously activated following various stimuli, it would be of
great importance to understand their functional interrelation-
ship.
To con¢rm functional interaction between the two phos-
pholipases critically involved in signal transduction, we per-
formed reconstitution analyses by cotransfecting HEK293
cells with signaling PLA2s (cPLA2 and sPLA2-IIA) and either
of the two PLD enzymes. Our results have provided evidence
that PLD2, but not PLD1, has the ability to enhance signaling
PLA2-promoted AA release and attendant COX-2-dependent
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PGE2 generation, and conversely, activation of PLD2, but not
PLD1, is facilitated by signaling PLA2s.
2. Materials and methods
2.1. Materials
cDNAs for mouse cPLA2, mouse sPLA2-IIA, and human COX-2
were described previously [3,4]. cDNAs for human PLD1b and human
PLD2 subcloned into the mammalian expression vector pcDNA3.1(+)
(Invitrogen) were kindly provided by Dr. S.H. Ryu (Pohang Univer-
sity of Science and Technology). The mammalian expression vector
pcDNA3.1/zeo(+), geneticin and zeocin were purchased from Invitro-
gen. A23187 was purchased from Calbiochem. Human interleukin-1L
(IL-1L) was obtained from Genzyme. [3H]AA and [3H]oleic acid (OA)
were purchased from Amersham Pharmacia Biotech. TRIzol reagent,
Lipofectamine PLUS and Opti-MEM were from Life Technologies.
Phorbol myristate acetate (PMA) was purchased from Sigma. Other
chemicals were obtained from Wako. Culture of HEK293 cells was
described previously [3].
2.2. Establishment of PLA2/PLD transfectants
Human PLD1b and PLD2 cDNAs subcloned into pcDNA3.1(+)
were each transfected into HEK293 cells using Lipofectamine PLUS
according to the manufacturer’s instruction. Brie£y, 1 Wg of the plas-
mid was mixed with 4 Wl of Lipofectamine and 6 Wl of PLUS reagent
in 200 Wl of Opti-MEM medium, left for 15 min, and then added to
cells that had attained 70% con£uency in 6-well plates (Iwaki Glass)
in 1 ml of Opti-MEM. After incubation for 6 h, 2 ml of fresh culture
medium (RPMI 1640 (Nissui Pharmaceutical) containing 10% fetal
calf serum (FCS)) was added. After 18 h, the medium was replaced
with 2 ml of fresh medium, and culture was continued for 3 days.
Then the cells were cloned by limiting dilution in 96-well plates (Iwaki
Glass) in culture medium supplemented with 800 Wg/ml geneticin.
After culture for 3 weeks, wells containing a single colony were chos-
en, and the expression of each PLD was assessed by RNA blotting.
Establishment of HEK293 cells stably overexpressing mouse cPLA2
or mouse sPLA2-IIA was described previously [3].
In order to establish double transfectants stably coexpressing PLA2
and PLD enzymes, cells expressing each PLD were subjected to a
second transfection with cPLA2 or sPLA2-IIA cDNA subcloned
into pcDNA3.1/zeo(+). After selection in culture medium containing
50 Wg/ml zeocin in 96-well plates, single colonies were picked up and
expanded. Expression of each enzyme was assessed by RNA blot-
ting.
2.3. Activation of PLA2
All procedures were described in our previous reports [3,4]. Brie£y,
HEK293 cells (5U104/ml) were seeded into each well of 24-well cul-
ture plates (Iwaki Glass) in 1 ml of culture medium. After culture for
3 days, the cells were prelabeled with 10 WCi/ml [3H]AA and cultured
for another day. Then the cells were washed once with culture me-
dium and incubated with 250 Wl of 10 WM A23187 in medium con-
taining 1% FCS for 30 min or 1 ng/ml IL-1L in medium containing
10% FCS for 4 h. The percentage release of [3H]AA was calculated
using the formula [S/(S+P)]U100, where S and P are the radioactiv-
ities measured in equal portions of the supernatant and cell pellet,
respectively.
2.4. Activation of PLD
PLD activity was assessed by its unique transphosphatidylation
reaction [12]. Cells (5U104/ml) were seeded into 12-well plates (Iwaki
Glass) in 1.5 ml of culture medium, cultured for 3 days, and then
incubated with 1 WCi/ml [3H]OA in culture medium for another day.
After washing twice with medium containing 1% FCS, the cells were
cultured with or without 10 WM A23187 and 2 WM PMA in medium
containing 1% FCS for 30 min in the presence of 1% ethanol. After
removing the supernatants, the cells were lysed promptly by adding a
mixture of 2 ml of methanol, 1 ml of chloroform and 300 Wl of 0.1%
sodium dodecyl sulfate. Total lipids were then extracted by the meth-
od by Bligh and Dyer [31] and developed by thin-layer chromatogra-
phy on silica 60 gel plates (Merck DuPont) with a solvent system of
ethyl acetate/trimethyl pentane/acetic acid/water = 52/8/12/40. After
drying, the plates were developed again to the same direction with
the same solvent. The zones on the silica gel corresponding to phos-
phatidylethanol (PEt) were identi¢ed by comparing the mobility with
that of authentic standard, which was visualized with iodine vapor,
and were scraped into a vial. The associated radioactivity was counted
using a liquid L-scintillation counter (Aloka).
2.5. RNA blotting
Approximately equal amounts (V5 Wg) of total RNA obtained
from the transfected cells were applied to individual lanes of 1.2%
(w/v) formaldehyde^agarose gels, electrophoresed, and transferred to
Immobilon-N membranes (Millipore). The resulting blots were then
probed with the relevant cDNA probes, which had been labeled with
[32P]dCTP (Amersham Pharmacia Biotech) by random priming (Ta-




The expression levels of each enzyme in HEK293 cells
transfected with PLA2s (cPLA2 and sPLA2-IIA) and PLDs
(PLD1 and PLD2) alone or in combination, as assessed by
RNA blotting, are shown in Fig. 1. When cells transfected
with cPLA2 alone were stimulated with A23187 for 30 min
(immediate response) or with IL-1 for 4 h (delayed response),
AA release was increased signi¢cantly relative to that by rep-
licate control cells in both responses (Fig. 2), as described
previously [3,4]. AA release by cells expressing PLD1 or
PLD2 alone was comparable to that by control cells. Remark-
ably, AA release by cells expressing cPLA2 in combination
with PLD2, but not with PLD1, was markedly augmented,
reaching a several-fold higher level than that by cells express-
ing cPLA2 alone in both A23187- and IL-1-induced responses
(Fig. 2). Since PLD1 has been shown to be activated by PMA
[13^16], we next stimulated cPLA2/PLD1 cotransfectants with
A23187 in the presence of PMA. Despite increased PLD1
activity (see below), however, AA release by these cells was
similar to that by replicate cPLA2-expressing cells (data not
shown). Expression of sPLA2-IIA also led to signi¢cant in-
crease in A23187- and IL-1-induced AA release (Fig. 3), as
described previously [3^5,8]. This sPLA2-mediated AA release
Fig. 1. Expression of PLA2 and PLD enzymes in HEK293 transfec-
tants. Expression of cPLA2, sPLA2-IIA, PLD1 and PLD2 in
HEK293 transfectants was assessed by RNA blotting.
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was also enhanced markedly by coexpression with PLD2, but
not with PLD1 (Fig. 3).
3.2. COX-2-dependent PGE2 generation
IL-1-stimulated increase in AA release by cPLA2- or
sPLA2-IIA-transfected HEK293 cells was accompanied by ac-
cumulation of PGE2 in the culture medium [3^5,8]. As shown
in Fig. 4, PGE2 generation by cells expressing cPLA2 or
sPLA2-IIA alone increased modestly compared with that by
control cells, and that by cells coexpressing cPLA2 or sPLA2-
IIA and PLD2 reached levels several-fold higher than that by
cells expressing each PLA2 alone. In contrast, no signi¢cant
increase in PGE2 generation was observed in cells expressing
PLD1 or PLD2 alone, and PGE2 generation by cells coex-
pressing cPLA2 and PLD1 was comparable to that by cells
expressing cPLA2 alone.
IL-1-dependent delayed PGE2 generation depends entirely
on inducible COX-2 [3^5,8]. Of interest, the expression level
of COX-2 in cells expressing PLD2 alone was higher than that
in control cells or in cells expressing cPLA2 and PLD1, alone
or in combination (Fig. 4, top panel). COX-2 expression in
cells coexpressing cPLA2 and PLD2 was similar to that in cells
expressing PLD2 alone, indicating that the PLD2-mediated,
but not cPLA2-mediated, signals crucially in£uence the
COX-2 induction machinery. Cells expressing PLD2 alone
did not produce PGE2 appreciably irrespective of increased
COX-2 expression (Fig. 4), most likely because AA supply
was limited in these cells (Fig. 2). sPLA2-IIA alone had the
ability to enhance COX-2 expression (Fig. 4, top panel), as
reported previously [5,9], and coexpression of sPLA2-IIA and
PLD2 augmented it further (Fig. 4, top panel). COX-2 expres-
sion was undetectable in all clones without IL-1 stimulation
(data not shown).
3.3. PLD activation
We next examined the e¡ect of PLA2s on PLD activation.
To this end, cells were treated for 30 min with A23187 and
PMA in the presence of ethanol, and the formation of PEt, a
reaction product of PLD-mediated transphosphatidylation
[12], was assessed. As shown in Fig. 5, PLD activity in cells
transfected with PLD1 and PLD2 increased 2- and 1.4-fold,
respectively, compared with that in control cells or cells ex-
pressing each PLA2 alone. Notably, more PEt was produced
Fig. 2. AA release by cPLA2/PLD transfectants. [3H]AA-prelabeled
HEK293 transfectants expressing cPLA2, PLD1 and PLD2, alone or
in combination, were stimulated for 30 min with A23187 or for 4 h
with IL-1. A representative result of four independent experiments
is shown.
Fig. 3. AA release by sPLA2-IIA/PLD transfectants. [3H]AA-prela-
beled HEK293 transfectants expressing sPLA2-IIA, PLD1 and
PLD2, alone or in combination, were stimulated for 30 min with
A23187 or for 4 h with IL-1. A representative result of three inde-
pendent experiments is shown.
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in cells coexpressing PLD2 and either cPLA2 or sPLA2-IIA
than in cells expressing PLD2 alone, whereas the PLD1-medi-
ated increase in PEt formation was not altered signi¢cantly
when combined with either PLA2.
4. Discussion
Interrelationships between di¡erent classes of phospholi-
pase have been shown to signi¢cantly a¡ect signal transduc-
tion systems in activated cells. PLC-mediated production of
inositol triphosphate triggers intracellular Ca2 mobilization,
which is a prerequisite for cPLA2 activation [1]. Conversely,
the tyrosine kinase-coupled PLC-Q isozymes are stimulated by
AA, which is supplied by cPLA2, in the presence of the micro-
tubule-associated protein tau or tau-like protein AHNAK
[33,34]. Prior activation of cPLA2 modulates the action of
signaling sPLA2s probably through destabilizing sPLA2-tar-
geted membrane structures [3,10,11,35], while sPLA2s can ac-
tivate cPLA2 through the sPLA2 receptor-dependent [36,37]
and -independent [38] processes.
Although the precise regulatory mechanisms for intracellu-
lar activation of PLD enzymes are not yet fully understood,
several previous works have supported the idea that PLA2
and PLD also display some functional crosstalk. For instance,
PLD has been suggested to act as an upstream regulator of
PLA2 activity in neutrophils, where AA release was sup-
pressed by alcohol and PA phosphatase inhibitors, which dis-
turb the PLD pathway, and was restored by PA and DAG
[24^26]. However, these pharmacological studies do not nec-
essarily de¢ne the involvement of particular PLD isozymes in
the cPLA2-regulatory processes. More recently, a study using
dominant-negative forms of PLD variants has revealed the
involvement of PLD2, but not PLD1, in the insulin-induced
production of PA, which promotes membrane translocation
of raf-1 and subsequent activation of MAPK [27], thereby
leading in turn to cPLA2 activation [2]. A requirement for
PLA2 for PLD activation has been suggested by the demon-
strations that PLD2, but not PLD1, was activated by unsatu-
rated fatty acids, such as OA and AA, in concert with PIP2 in
vitro [28], and that inhibitors and antisense for cPLA2 re-
duced A23187-induced PLD2 activation in vivo [30]. More-
over, reduced PLD2 activation by cPLA2 inhibitors was
restored by supplementing the cells with lysophosphatidylcho-
line, a primary product of cPLA2 [30]. In marked contrast,
activation of cPLA2 and PLD1 occurred independently in
human monocytes [29].
Our present study, by employing a cotransfection strategy,
has con¢rmed the functional interaction between signaling
PLA2s (cPLA2 and sPLA2-IIA) and PLD2. Cotransfection
of either of the signaling PLA2s and PLD2, but not PLD1,
markedly augmented AA release (indicative of PLA2 action)
and PEt formation (indicative of PLD activation), providing
further support for the hypothesis that both pathways are
functionally interrelated. Moreover, we have shown that
PLD2, but not PLD1, facilitates the induced expression of
COX-2, which lies downstream of cPLA2 and sPLA2-IIA in
the delayed PG biosynthetic pathway [3^5,8]. Thus, the PLD2
pathway signi¢cantly a¡ects cellular capacity to produce PGs.
The molecular mechanisms whereby signaling PLA2s and
PLD2 a¡ect each other’s functions are unknown at present.
The ¢ndings that the activity of PLD2, but not PLD1, is
modulated by the PLA2 reaction products [28,30] may ex-
Fig. 4. IL-1-induced PGE2 generation and COX-2 expression in
PLA2/PLD transfectants. HEK293 transfectants expressing cPLA2,
sPLA2-IIA, PLD1 and PLD2, alone or in combination, were stimu-
lated for 4 h with IL-1, and PGE2 production and COX-2 mRNA
expression (assessed by RNA blotting; top panel) were examined. A
representative result of three independent experiments is shown.
Fig. 5. PLD activation in PLA2/PLD transfectants. [3H]OA-prela-
beled HEK293 transfectants expressing cPLA2, sPLA2-IIA, PLD1
and PLD2, alone or in combination, were stimulated for 30 min
with A23187 and PMA, and [3H]PEt formation was examined. Val-
ues indicate the percent radioactivity associated with PEt relative to
that incorporated into total phospholipids. A representative result
of three independent experiments is shown.
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plain, at least in part, why only PLD2 can be stimulated by
signaling PLA2s. Moreover, activation of the MAPK pathway
via the PLD2-dependent route [27] could be sequentially
linked to cPLA2 activation [2] as well as COX-2 induction
[39]. Since the action of sPLA2-IIA depends on prior activa-
tion of cPLA2 [3,10,11], PLD2-mediated activation of a low
level of endogenous cPLA2 may eventually cause subsequent
activation of sPLA2-IIA in HEK293 cells. Interestingly, both
PLD2 [20] and sPLA2-IIA [8] have been shown to reside in
caveolae. Colocalization of these enzymes in this particular
membrane compartment may assist adequate presentation of
the PLA2 reaction products, which would facilitate the acti-
vation of PLD2. Since PA, a PLD product, is a preferred
substrate for sPLA2-IIA [40], its production by PLD2 in the
caveolar membrane may further accelerate sPLA2-IIA-di-
rected membrane hydrolysis. This speculation is in line with
the notion that sPLA2-IIA requires stimulus-induced mem-
brane modi¢cations for its proper hydrolytic action [41].
Thus, the PLA2/PLD2 crosstalk may represent an unexplored
positive-feedback ampli¢cation loop of the signal transduction
cascade.
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